Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;19(5):197-207.
doi: 10.1007/s11899-024-00737-8. Epub 2024 Aug 27.

Systemic Mastocytosis: State of the Art

Isabel Farmer  1 , Deepti H Radia  2
Affiliations
Review

Systemic Mastocytosis: State of the Art

Isabel Farmer et al. Curr Hematol Malig Rep. 2024 Oct.

Abstract

Purpose of review: Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), there has been a wealth of new research in therapeutic targeting of the pathogenic C-KIT D816V mutation.

Recent findings: Avapritinib, the first licensed drug in SM capable of disease modification alongside the increasingly potent, oral and highly selective KIT tyrosine kinase inhibitors (TKIs) Bezuclastinib and now Elenestinib have enabled the prospect of long-term remissions. Studies have shown improved survival and symptomatic control in patients with SM. Of great triumph, this has been achieved in an outpatient setting with apparent tolerable and minimal toxicity. The importance of molecular profiling is being demonstrated in administering combination therapies for SM with an associated haematological neoplasm (AHN), allowing more personalised and streamlined treatment regimes. This review focuses on current management strategies of SM, focusing on state-of-the-art directed therapies, the evidence behind their use with presentation of two clinical cases to highlight key messages.

Keywords: Avapritinib; Bezuclastinib; Midostaurin; Systemic mastocytosis; KIT inhibitors; Tyrosine kinase inhibitors.

PubMed Disclaimer

References

    1. Piris-Villaespesa, M. and Alvarez-Twose, I. (2020) ‘Systemic mastocytosis: Following the tyrosine kinase inhibition roadmap’, Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.00443 .
    1. Gotlib, J. et al. (2022) ‘Proposed European Competence Network on mastocytosis—American initiative in mast cell diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis’, The Journal of Allergy and Clinical Immunology: In Practice, 10(8). https://doi.org/10.1016/j.jaip.2022.05.034 .
    1. Choi JK, et al. Fifth edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues: Acute lymphoblastic leukemias, mixed-phenotype acute leukemias, myeloid/lymphoid neoplasms with eosinophilia, dendritic/histiocytic neoplasms, and genetic tumor syndromes. Mod Pathol. 2024;37(5):100466. https://doi.org/10.1016/j.modpat.2024.100466 . - DOI - PubMed
    1. Akin C. Tyrosine kinase inhibitors in non-advanced systemic mastocytosis. Immunol Allergy Clin North Am. 2023;43(4):743–50. https://doi.org/10.1016/j.iac.2023.05.001 . - DOI - PubMed
    1. Mesa RA, et al. Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the touchstone SM patient survey. Cancer. 2022;128(20):3691–9. https://doi.org/10.1002/cncr.34420 . - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources